Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo

Autor: Eike Hoffmann, Cornelia Fischer, Ann B. Hill, Martina Schmittnaegel, Stefan Bissinger, Michael W. Munks, Hendrik Knoetgen, Christian Klein, Richard A. Kroczek, Frank Herting, Sabine Imhof-Jung, Verena Brand

Publikováno v: mAbs
article-version (VoR) Version of Record

Simulating a viral infection in tumor cells is an attractive concept to eliminate tumor cells. We previously reported the molecular design and the in vitro potency of recombinant monoclonal antibodies fused to a virus-derived peptide MHC class I comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::594c344a5c6ddb3ab1d8bc70372b680b
http://europepmc.org/articles/PMC7668529

Activation of cytomegalovirus-specific CD8

Autor: Martina, Schmittnaegel, Christian, Klein, Victor, Levitsky, Hendrik, Knoetgen

Publikováno v: Oncoimmunology

Imposing antigenicity on tumor cells is a key step toward successful cancer-immunotherapy. A cytomegalovirus-derived peptide recombinantly fused to a major histocompatibility class I complex and a monoclonal antibody can be targeted to tumor cells by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::acd7aa84afe08d426360e2c9982abeb1
https://pubmed.ncbi.nlm.nih.gov/26942061

Activation of cytomegalovirus-specific CD8 ⁺ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes.

Autor: Schmittnaegel M; ROCHE Pharma Research and Early Development: Large Molecule Research; ROCHE Innovation Center ; Penzberg, Germany., Klein C; ROCHE Pharma Research and Early Development: Discovery Oncology; ROCHE Innovation Center ; Zurich, Switzerland., Levitsky V; ROCHE Pharma Research and Early Development: Discovery Oncology; ROCHE Innovation Center ; Zurich, Switzerland., Knoetgen H; ROCHE Pharma Research and Early Development: Large Molecule Research; ROCHE Innovation Center ; Penzberg, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2015 May 29; Vol. 5 (1), pp. e1052930. Date of Electronic Publication: 2015 May 29 (Print Publication: 2016).